

Re-organisation of Wyeth's Havant site

2nd March 2006

As part of a global strategy to improve efficiency and better serve customers across the world, Wyeth is implementing a number of changes across its global manufacturing network. These changes include the re-organisation of the Company's operations at its Havant site in the UK.

Havant has been chosen as a global centre of excellence for the packaging and distribution of some of the company's most advanced medicines and vaccines, including an advanced treatment for rheumatoid arthritis, vaccines against meningitis, and a new antibiotic.

As part of the re-organisation, certain other activities, including production of over-the-counter medicines and other packaging and finishing work, will be consolidated at other Wyeth sites or move to 3rd party manufacturers.

Changes to the Havant workforce will also start to be phased in over the next two years as a result of the re-organisation. Approximately 200 positions across all levels and across all departments may be affected, although it is estimated that at least a third of these could be absorbed by retirements, redeployments, voluntary severance and normal staff turnover. Wyeth will be offering a competitive severance package, including out-placement support, to all affected employees. The Havant site currently employs almost 700 people.

"The re-organisation demonstrates a renewed commitment to the site," said Plant Director, Dr Jim Neville. "The changes put Havant at the heart of Wyeth's global packaging and distribution operations, supporting the success of some of the Company's most important and successful products. The decision to take on this role is testimony to the skills, expertise and commitment of the Havant workforce."

Wyeth at Havant

Wyeth has been part of the Havant business community since 1957. The Havant site currently employs almost 700 people.

About Wyeth

Wyeth is one of the world's leading pharmaceutical companies with a major focus on developing innovative new medicines to improve health and well-being.

In the UK, Wyeth is one of the largest pharmaceutical companies with a broad portfolio of leading products across a wide range of treatment areas, including gastro-intestinal disease, mental health, women's healthcare, haemophilia, prostate cancer, rheumatology, infectious disease, dermatology and transplantation. Wyeth is also a major force in preventative medicine through its Wyeth Vaccines division.

In total, Wyeth employs almost 2,000 people in the UK at sites in Havant and Gosport in Hampshire, and at Taplow, Slough, and Maidenhead in Berkshire.